People · Operator
Named in public records as an officer, director or promoter · active 2016–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Xylocor Therapeutics, Inc. | — | Biotechnology | Series B | $21.4M | $126.0M | 2016 |
James Cohen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Cohen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Glenn Batchelder | 1 | 4 |
| Fouad Azzam, Ph.D. | 1 | 1 |
| Aidan F. King | 1 | 1 |
| Michael F. Powell, Ph.D. | 1 | 1 |
| Todd K. Rosengart, M.D. | 1 | 1 |
| Albert Gianchetti | 1 | 1 |
| Todd Rosengart | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.